Australia · Delayed Price · Currency is AUD Recce Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
A novel broad-spectrum antibiotic gel is in late-stage trials for diabetic foot infections, with commercial launch targeted for 2024 in Indonesia and ASEAN. Strong clinical and preclinical data, global partnerships, and U.S. Department of Defense support position the product for rapid market expansion and leadership in anti-infectives.
Fiscal Year 2025
-
A new class of synthetic antibiotics is advancing through late-stage Phase III trials in Indonesia and Australia, targeting large unmet needs in diabetic foot ulcer infections. Expedited regulatory pathways, strong government support, and robust funding position the company for near-term commercial entry in ASEAN and global markets.
Fiscal Year 2024
-
The meeting covered strong clinical progress, robust financial positioning, and strategic partnerships, with a focus on global commercialization of anti-infective therapies. Shareholders engaged in detailed Q&A on market opportunities, pricing, and executive matters, and all resolutions were put to vote.